-
Atezolizumab combined with immunogenic salvage chemoimmunotherapy in patients with transformed diffuse large B-cell lymphoma. Haematologica (IF 8.2) Pub Date : 2024-07-18 Tamer Othman, Paul Frankel, Pamela Allen, Leslie L Popplewell, Geoffrey Shouse, Tanya Siddiqi, Alexey V Danilov, Nora Ruel, Shari Daniels, Lacolle Peters, Stella Khoo, Steven T Rosen, Elad Sharon, Miguel Villalona-Calero, Christopher Ruel, Joseph Tuscano, Alex F Herrera
Patients with relapsed/refractory (R/R) transformed diffuse large B-cell lymphoma (DLBCL) from indolent B-cell lymphomas, including Richter transformation (RT), have a poor prognosis. PD-1/PD-L1 antibodies produce modest objective and complete response rates (ORR and CRR) in B-NHL as monotherapy but may synergize with immunogenic chemotherapies like gemcitabine and oxaliplatin (GemOx). Thus, we evaluated
-
A targeted gene signature stratifying mediastinal gray zone lymphoma into classical HL-like or PMBL-like subtypes. Haematologica (IF 8.2) Pub Date : 2024-07-18 Grazia Gargano, Maria Carmela Vegliante, Flavia Esposito, Susanna A Pappagallo, Elena Sabattini, Claudio Agostinelli, Stefano A Pileri, Valentina Tabanelli, Maurilio Ponzoni, Luisa Lorenzi, Fabio Facchetti, Arianna Di Napoli, Marco Lucioni, Marco Paulli, Lorenzo Leoncini, Stefano Lazzi, Stefano Ascani, Giuseppina Opinto, Gian Maria Zaccaria, Giacomo Volpe, Paolo Mondelli, Antonella Bucci, Laura Selicato
Not available.
-
Risk of infections in multiple myeloma. A population-based study on 8672 multiple myeloma patients diagnosed 2008-2021 from the Swedish Myeloma Registry. Haematologica (IF 8.2) Pub Date : 2024-07-18 Cecilie Hveding Blimark, Kristina Carlson, Christopher Day, Sigrun Einarsdottir, Gunnar Juliusson, Moshtak Karma, Dorota Knut-Bojanowska, Gunnar Larfors, Ingemar Turesson, Mariana Villegas-Scivetti, Ingigerdur Sverrisdóttir
In multiple myeloma (MM), advancements in treatments and toxicity management have enhanced survival rates. This, coupled with shifting age demographics in MM, necessitates an updated understanding of infection risks in MM patients compared to the general population. Using Swedish population-based registries, we investigated the incidence of infections in 8,672 Swedish symptomatic MM patients diagnosed
-
Sequencing of cellular therapy and bispecific antibodies for the management of diffuse large B-cell lymphoma. Haematologica (IF 8.2) Pub Date : 2024-07-18 Megan Melody, Leo I Gordon
Historically, management of relapsed or refractory (R/R) Diffuse large B-cell (DLBCL) following first-line chemoimmunotherapy has been second-line chemotherapy, followed by high-dose chemotherapy and consolidative autologous hematopoietic stem cell transplantation (auto-HSCT), resulting in durable remissions in approximately 40% of patients. In 2017, chimeric antigen receptor (CAR) T-cell therapy changed
-
No clear benefit of preventive cranial radiotherapy in childhood Philadelphia-positive acute lymphoblastic leukemia: a retrospective analysis of the EsPhALL2010 study. Haematologica (IF 8.2) Pub Date : 2024-07-18 Valentino Conter, Maria Grazia Valsecchi, Paola De Lorenzo, Virginie Gandemer, Mats Heyman, Vaskar Saha, Paulina Diaz, Chi-Kong Li, Andishe Attarbaschi, Gabriele Escherich, Jan Stary, Martin Schrappe, Rob Pieters, Gunnar Cario, Andrea Biondi
Not available.
-
Multiple myeloma in the young: insights on prognosis, clinical features and treatment outcome derived from nationwide German registry data and a nested multicenter sample. Haematologica (IF 8.2) Pub Date : 2024-07-18 Abdulaziz Kamili, Paymon Ahmadi, Lisa Leypoldt, Franziska Marquard, Christoph Schaefers, Ricardo Kosch, Frederik Peters, Henrik Kusche, Tanja Zamrik, Christine Hanoun, Maximilian Seib, Evgenii Shumilov, Theo Leitner, Cyrus Khandanpour, Carsten Bokemeyer, Katja Weisel, Susanne Ghandili
Not available.
-
Minimal residual disease assessment in transplant-eligible patients with multiple myeloma: real-world applications of multiparametric flow cytometry-DURAClone (CAREMM-2104). Haematologica (IF 8.2) Pub Date : 2024-07-18 Ari Ahn, Sung-Soo Park, Yonggoo Kim, Jung Yeon Lee, Jong-Mi Lee, Jin Jung, Myungshin Kim, Chang-Ki Min
Not available.
-
Mimicry of inherited red cell disorders: the result of somatic mutations in a clonal myeloid disease. Haematologica (IF 8.2) Pub Date : 2024-07-18 Marshall A Lichtman, Audrey N Jajosky
Not available.
-
A new frontier in the battle against infant acute lymphoblastic leukemia. Haematologica (IF 8.2) Pub Date : 2024-07-18 Daisuke Tomizawa
Not available.
-
Co-transfection of murine NXPE2 and murine glycophorin A confers reactivity with Ter-119. Haematologica (IF 8.2) Pub Date : 2024-07-18 Gregory R Keele, Ariel M Hay, Nadia K Holness, Arijita Jash, Sarah E Ewald, Callan O'Connor, Matthew Vincent, Monika Dzieciatkowska, Angelo D'Alessandro, Gary A Churchill, James C Zimring
Not available.
-
Polytypic B cells, monotypic/monoclonal B-cell proliferations, and neoplastic T cells diverge from TET2-/DNMT3A-mutant clonal hematopoiesis in follicular helper T-cell lymphomas. Haematologica (IF 8.2) Pub Date : 2024-07-18 Natasha E Lewis, Kseniya Petrova-Drus, Rohan Sardana, Sarah Huet, Qi Gao, Shenon Sethi, Chad Vanderbilt, Wenbin Xiao, Mikhail Roshal, Jeeyeon Baik, Himanshu Bhurtel, Alison J Moskowitz, Steven M Horwitz, Ahmet Dogan
Not available.
-
Reference interval of free light chains ratio in patients with end-stage renal disease on chronic hemodialysis. Haematologica (IF 8.2) Pub Date : 2024-07-18 Camila Peña, Ricardo Valjalo, Ramón Pérez, Marco Álvarez, Pablo Bustamante, Esteban Forray, Viviana Balboa, Alexis Bondi
Not available.
-
Umbilical cord blood T cells can be isolated and enriched by CD62L selection for use in 'off the shelf' chimeric antigen receptor T-cell therapies to widen transplant options. Haematologica (IF 8.2) Pub Date : 2024-07-11 Christos Georgiadis, Lauren Nickolay, Farhatullah Syed, Hong Zhan, Soragia Athina Gkazi, Annie Etuk, Ulrike Abramowski-Mock, Roland Preece, Piotr Cuber, Stuart Adams, Giorgio Ottaviano, Waseem Qasim
Umbilical cord blood (UCB) T cells exhibit distinct naive ontogenetic profiles and may be an attractive source of starting cells for the production of chimeric antigen receptor (CAR) T cells. Pre-selection of UCB-T cells on the basis of CD62L expression was investigated as part of a machine-based manufacturing process, incorporating lentiviral transduction, CRISPR-Cas9 editing, T-cell expansion and
-
Germline variants in acquired aplastic anemia: current knowledge and future perspectives. Haematologica (IF 8.2) Pub Date : 2024-07-11 Peicheng Wang, Wanzhi Jiang, Tianyi Lai, Qi Liu, Yingying Shen, Baodong Ye, Dijiong Wu
Aplastic anemia (AA) is a disease characterized by hematopoiesis failure, bone marrow aplasia, and pancytopenia. It can be inherited or acquired. Although acquired AA is believed to be immune-mediated and random, new evidence suggests an underlying genetic predisposition. Besides confirmed genomic mutations that contribute to inherited AA (such as pathogenic mutations of TERT and TERC), germline variants
-
Combinatorial strategies targeting NEAT1 and AURKA as new potential therapeutic options for multiple myeloma. Haematologica (IF 8.2) Pub Date : 2024-07-11 Noemi Puccio, Gloria Manzotti, Elisabetta Mereu, Federica Torricelli, Domenica Ronchetti, Michela Cumerlato, Ilaria Craparotta, Laura Di Rito, Marco Bolis, Valentina Traini, Veronica Manicardi, Valentina Fragliasso, Yvan Torrente, Nicola Amodio, Niccolò Bolli, Elisa Taiana, Alessia Ciarrochi, Roberto Piva, Antonino Neri
Multiple myeloma (MM) is a dreadful disease, marked by the uncontrolled proliferation of clonal plasma cells (PCs) within the bone marrow (BM). MM is characterized by a highly heterogeneous clinical and molecular background, supported by severe genomic alterations. Important deregulation of long non-coding RNAs (lncRNAs) expression has been reported in MM patients, influencing progression and therapy
-
Excellent outcome of children/adolescents with primary mediastinal large B-cell lymphoma treated with FAB/LMB-based chemotherapy regimen with rituximab. Haematologica (IF 8.2) Pub Date : 2024-07-11 Marie Emilie Dourthe, Anne Auperin, Charlotte Rigaud, Melissa Barbati, Jacinthe Bonneau, Nimrod Buchbinder, Marie-Laure Couec, Peggy Dartigues, Stéphane Ducassou, Nathalie Garnier, Stéphanie Haouy, Bénédicte Jonca, Anne Jourdain, Amaury Leruste, Thierry Molina, Françoise Montravers, Marlène Pasquet, Aurélie Phulpin, Maryline Poirée, Mathieu Simonin, Alexandra Spiegel, Arnauld Verschuur, Thierry Leblanc
Not available.
-
Single-point and kinetics of peripheral residual disease by mass spectrometry to predict outcome in patients with high risk smoldering multiple myeloma included in the GEM-CESAR trial. Haematologica (IF 8.2) Pub Date : 2024-07-11 Noemí Puig, Cristina Agulló, Teresa Contreras, José-Juan Pérez, Irene Aires, María-José Calasanz, Ramón García-Sanz, Sergio Castro, Joaquín Martínez-López, Paula Rodríguez-Otero, Verónica González-Calle, Marta S González, Albert Oriol, Norma C Gutiérrez, Rafael Ríos-Tamayo, Laura Rosiñol, Miguel-Ángel Álvarez, Joan Bargay, Ana-Pilar González-Rodríguez, Adrián Alegre, Fernando Escalante, María-Belén
The value of quantitative immunoprecipitation mass spectrometry (QIP-MS) to identify the M-protein is being investigated in patients with monoclonal gammopathies but no data are yet available in high-risk smoldering myeloma (HRsMM). We have therefore investigated QIP-MS to monitor peripheral residual disease (PRD) in 62 HRsMM patients enrolled in the GEM-CESAR trial. After 24 cycles of maintenance
-
New precision medicine weapons for targeted treatment of high-risk B-cell precursor acute lymphoblastic leukemia. Haematologica (IF 8.2) Pub Date : 2024-07-11 Sinisa Dovat, Joseph Schramm
Not available.
-
Rituximab maintenance after bendamustine-based treatment for follicular lymphoma and mantle cell lymphoma may exert a negative influence on SARS-CoV-2 infection outcomes. Haematologica (IF 8.2) Pub Date : 2024-07-11 Ángel Serna, Víctor Navarro, Gloria Iacoboni, Laia López, Juan-Manuel Sancho, Eva González-Barca, Alberto López-García, Raúl Córdoba, Adolfo Sáez, Ana Jiménez Ubieto, Ainara Ferrero, Tomás García, Ángela Sánchez, Cristina García, Marc Bosch, Alba Cabirta, Moraima Jiménez, Ana Marín-Niebla, Francesc Bosch, Pau Abrisqueta
Not available.
-
Extending duration of letermovir prophylaxis in haploidentical stem cell transplantation. Haematologica (IF 8.2) Pub Date : 2024-07-11 Pongthep Vittayawacharin, Benjamin J Lee, Shawn Griffin, Jean Doh, Julie Smith, Hannah Nam, Emily Blodget, Deepa Jeyakumar, Piyanuch Kongtim, Stefan O Ciurea
Not available.
-
Microbiota signature of oral chronic graft-versus-host disease 6+ years after transplantation. Haematologica (IF 8.2) Pub Date : 2024-07-11 Armin Rashidi, Lang Liang, Ted Gooley, Philippe P Hujoel, Alex Zevin, Marilynn Rothen, Mary K Hagstrom, Corey Cutler, Stephanie J Lee, David R Dean, Hervé Y Sroussi, Nathaniel S Treister
Not available.
-
The Gordian knot: ruxolitinib or transplants for high-risk myelofibrosis. Haematologica (IF 8.2) Pub Date : 2024-07-11 Robert Peter Gale, Giovanni Barosi
Not available.
-
Have we truly uncovered the key to primary vitreoretinal lymphoma's pathway to the central nervous system? Haematologica (IF 8.2) Pub Date : 2024-07-11 Liang Wang
Not available.
-
A novel role of AURKA kinase in erythroblast enucleation. Haematologica (IF 8.2) Pub Date : 2024-07-04 Yuanlin Xu, Peijun Jia, Yating Li, Huan Zhang, Jingxin Zhang, Wanxin Li, Yazhe Zhen, Yan Li, Jiaming Cao, Tingting Zheng, Yihan Wang, Yanyan Liu, Xiuli An, Shijie Zhang
Generation of mammalian red blood cells requires the expulsion of polarized nuclei late in terminal erythroid differentiation. However, the mechanisms by which spherical erythroblasts determine the direction of nuclear polarization and maintain asymmetry during nuclear expulsion are poorly understood. Given the analogy of erythroblast enucleation to asymmetric cell division and the key role of Aurora
-
The importance of secondary cancer screening programs in Hodgkin lymphoma survivors. Haematologica (IF 8.2) Pub Date : 2024-07-04 Marco A Salvino, Eva Domingo-Domènech, Anna Sureda
Not available.
-
Response to DA-EPOCH-R is associated with activation of 'fitter' cytotoxic T-cells in patients with newly diagnosed double and triple hit high-grade B-cell lymphoma. Haematologica (IF 8.2) Pub Date : 2024-07-04 A Vera De Jonge, Wassilis S C Bruins, Carolien Duetz, Charlotte L B M Korst, Rosa Rentenaar, Meliha Cosovic, Merve Eken, Marie-Jose Kersten, Yorick Sandberg, Rozemarijn S Van Rijn, Rob Fijnheer, Pim Mutsaers, Vibeke K J Vergote, Djamila Issa, Aart Beeker, Yavuz M Bilgin, Otto Visser, Erik Van Werkhoven, Margaretha G M Roemer, Martine E D Chamuleau, Tuna Mutis
Not available.
-
Clonal evolution from B-cell acute lymphoblastic leukemia with BCR::ABL1 multilineage involvement to acute myeloid leukemia after multiple anti-CD19 chimeric antigen receptor T-cell therapy. Haematologica (IF 8.2) Pub Date : 2024-07-04 Mei-Jing Liu, Lan Dai, Li Yao, Kai-Wen Tan, Han-Yu Cao, Si-Man Huang, Chao-Ling Wan, Yuan-Hong Huang, Yang Zhang, Wen-Jie Gong, Sheng-Li Xue
Not available.
-
LSD1/KDM1A and GFI1B repress endothelial fate and induce hematopoietic fate in induced pluripotent stem cell-derived hemogenic endotheliums. Haematologica (IF 8.2) Pub Date : 2024-07-04 Huan Zhang, Marten Hansen, Franca Di Summa, Marieke Von Lindern, Nynke Gillemans, Wilfred F J Van IJcken, Arthur Flohr Svendsen, Sjaak Philipsen, Bert Van der Reijden, Eszter Varga, Emile Van den Akker
Differentiation of induced pluripotent stem cells (iPSCs) into hematopoietic lineages offers great therapeutic potential. During embryogenesis, hemogenic endothelium (HE) gives rise to hematopoietic stem and progenitor cells through the endothelial-to-hematopoietic transition (EHT). Understanding this process using iPSCs is key to generating functional hematopoietic stem cells (HSCs), a currently unmet
-
Acute myeloid leukemia at first relapse: approaching the precipice. Haematologica (IF 8.2) Pub Date : 2024-07-04 Xavier Calvo
Not available.
-
Moving forward in target antigen discovery for immunotherapy in acute myeloid leukemia. Haematologica (IF 8.2) Pub Date : 2024-06-27 Barbara Buldini, Elena Varotto
Not available.
-
Integration of genotypic data into clinical trial design and reporting in hereditary hemorrhagic telangiectasia could help personalize treatment. Haematologica (IF 8.2) Pub Date : 2024-06-27 Atieh Modarresi, Claire L Shovlin
Not available.
-
Respiratory syncytial virus and other vaccine-preventable infections in Multiple Myeloma. A population-based study on 8672 myeloma patients diagnosed 2008-2021 from the Swedish Myeloma Registry. Haematologica (IF 8.2) Pub Date : 2024-06-27 Sigrun Einarsdottir, Ingigerdur Sverrisdottir, Mariana Villegas-Scivetti, Chris Day, Ingemar Turesson, Gunnar Juliusson, Markus Hansson, Gunnar Larfors, Cecilie Hveding Blimark
Not available.
-
Safety and efficacy of flumatinib as later-line therapy in patients with chronic myeloid leukemia. Haematologica (IF 8.2) Pub Date : 2024-06-27 Yunfan Yang, Yuntao Liu, Hui Sun, Li Meng, Hai Lin, Chunyan Chen, Jianda Hu, Xuliang Shen, Minghui Duan, Yanli Zhang, Dilinazi Abulaiti, Jinghua Wang, Hongqian Zhu, Luoming Hua, Qing Leng, Chun Zhang, Lili Sun, Weiming Li, Huanling Zhu, Bingcheng Liu, Jianxiang Wang
To evaluate the efficacy and safety of flumatinib in the later-line treatment of Chinese patients with Philadelphia chromosome-positive chronic-phase chronic myeloid leukemia (CP-CML previously treated with tyrosine kinase inhibitors (TKIs). Patients with CML-CP were evaluated for the probabilities of responses including complete hematologic response (CHR), cytogenetic response, and molecular response
-
Blockade of the CD47/SIRPα checkpoint axis potentiates the macrophage-mediated anti-tumor efficacy of tafasitamab. Haematologica (IF 8.2) Pub Date : 2024-06-27 Alexander Biedermann, Maria Patra-Kneuer, Dimitrios Mougiakakos, Maike Büttner-Herold, Doris Mangelberger-Eberl, Johannes Berges, Christian Kellner, Sarah Altmeyer, Jörg Thomas Bittenbring, Christian Augsberger, Kristina Ilieva-Babinsky, Stefan Haskamp, Fabian Beier, Christopher Lischer, Julio Vera, Anja Lührmann, Simone Bertz, Simon Völkl, Benedikt Jacobs, Stefan Steidl, Andreas Mackensen, Heiko Bruns
Macrophages are one of the key mediators of the therapeutic effects exerted by monoclonal antibodies, such as the anti-CD19 antibody tafasitamab, approved in combination with lenalidomide for the treatment of relapsed or refractory (r/r) diffuse large B cell lymphoma (DLBCL). However, antibody-dependent cellular phagocytosis (ADCP) in the tumor microenvironment can be counteracted by increased expression
-
Core regions in immunoglobulin heavy chain enhancers essential for survival of non-Hodgkin lymphoma cells are identified by a CRISPR interference screen. Haematologica (IF 8.2) Pub Date : 2024-06-27 Marta Elżbieta Kasprzyk, Weronika Sura, Marta Podralska, Marta Kazimierska, Annika Seitz, Wojciech Łosiewski, Tomasz Woźniak, Jeroen E J Guikema, Arjan Diepstra, Joost Kluiver, Anke Van den Berg, Natalia Rozwadowska, Agnieszka Dzikiewicz-Krawczyk
Chromosomal translocations in non-Hodgkin lymphoma (NHL) result in activation of oncogenes by placing them under the regulation of immunoglobulin heavy chain (IGH) super-enhancers. Aberrant expression of translocated oncogenes induced by enhancer activity can contribute to lymphomagenesis. The role of the IGH enhancers in normal B-cell development is well established, but knowledge regarding the precise
-
Lysosomal acid lipase A modulates leukemia stem cell response to venetoclax/tyrosine kinase inhibitor combination therapy in blast phase chronic myeloid leukemia. Haematologica (IF 8.2) Pub Date : 2024-06-27 Mohd Minhajuddin, Amanda Winters, Haobin Ye, Shanshan Pei, Brett Stevens, Austin Gillen, Krysta Engel, Stephanie Gipson, Monica Ransom, Maria Amaya, Anagha Inguva, Maura Gasparetto, Mark J Althoff, Regan Miller, Ian Shelton, Hunter Tolison, Anna Krug, Rachel Culp-Hill, Angelo D'Alessandro, Daniel W Sherbenou, Daniel A Pollyea, Clayton Smith, Craig T Jordan
The treatment of blast phase chronic myeloid leukemia (bpCML) remains a challenge due at least in part to drug resistance of leukemia stem cells (LSCs). Recent clinical evidence suggests that the BCL-2 inhibitor venetoclax in combination with ABL-targeting tyrosine kinase inhibitors (TKIs) can eradicate bpCML LSCs. In this report, we employed preclinical models of bpCML to investigate the efficacy
-
FLT3 inhibitors potentially improve response rates in acute myeloid leukemia harboring t(6;9)(DEK::NUP214): The Mayo Clinic experience. Haematologica (IF 8.2) Pub Date : 2024-06-20 Clifford M Csizmar, Antoine N Saliba, Patricia T Greipp, Hassan Alkhateeb, Kebede H Begna, James M Foran, Naseema Gangat, William J Hogan, C Christopher Hook, Mark R Litzow, Abhishek A Mangaonkar, Jeanne M Palmer, Animesh Pardanani, Mithun V Shah, Ayalew Tefferi, Mehrdad Hefazi Torghabeh, Alexandra P Wolanskyj-Spinner, Mrinal M Patnaik, Scott H Kaufmann, Aref Al-Kali
Not available.
-
ASXL1/TET2 genotype-based risk stratification outperforms ASXL1 mutational impact and is independent of mutant variant allele fractions in chronic myelomonocytic leukemia. Haematologica (IF 8.2) Pub Date : 2024-06-20 Clifford M Csizmar, Mark Gurney, Rashmi Kanagal-Shamanna, Kelly Chien, Danielle Hammond, Terra L Lasho, Christy M Finke, Christopher Dean, Anuya Natu, Abhishek A Mangaonkar, Aref Al-Kali, Naseema Gangat, Ayalew Tefferi, Hassan Alkhateeb, Guillermo Garcia-Manero, Rami S Komrokji, Najla A Ali, Eric Padron, Guillermo Montalban-Bravo, Mrinal M Patnaik
Not available.
-
Long-term outcomes of newly diagnosed POEMS syndrome patients who received first-line lenalidomide-based therapy. Haematologica (IF 8.2) Pub Date : 2024-06-20 Xue-Min Gao, An-An Li, Hao Zhao, Kai-Ni Shen, Jian Li
Not available.
-
A first-in-class Wiskott-Aldrich syndrome protein activator with anti-tumor activity in hematologic cancers. Haematologica (IF 8.2) Pub Date : 2024-06-20 Filippo Spriano, Giulio Sartori, Jacopo Sgrignani, Laura Barnabei, Alberto J Arribas, Matilde Guala, Ana Maria Carrasco Del Amor, Meagan R Tomasso, Chiara Tarantelli, Luciano Cascione, Gaetanina Golino, Maria E Riveiro, Roberta Bortolozzi, Antonio Lupia, Francesco Paduano, Samuel Huguet, Keyvan Rezai, Andrea Rinaldi, Francesco Margheriti, Pedro Ventura, Greta Guarda, Giosuè Costa, Roberta Rocca, Alberto
Hematological cancers are among the most common cancers in adults and children. Despite significant improvements in therapies, many patients still succumb to the disease. Therefore, novel therapies are needed. The Wiskott-Aldrich syndrome protein (WASp) family regulates actin assembly in conjunction with the Arp2/3 complex, a ubiquitous nucleation factor. WASp is expressed exclusively in hematopoietic
-
Decision analysis for transplant candidates with primary myelofibrosis in the ruxolitinib era. Haematologica (IF 8.2) Pub Date : 2024-06-20 Yosuke Okada, Hideki Nakasone, Shunto Kawamura, Kosuke Takano, Kazuki Yoshimura, Masaharu Tamaki, Akari Matsuoka, Takuto Ishikawa, Tomohiro Meno, Yuhei Nakamura, Masakatsu Kawamura, Junko Takeshita, Nozomu Yoshino, Yukiko Misaki, Machiko Kusuda, Aki Tanihara, Shun-Ichi Kimura, Shinichi Kako, Yoshinobu Kanda
The recent progress with ruxolitinib treatment might improve quality-of-life as well as overall survival in patients with primary myelofibrosis (PMF). Therefore, the optimal timing of allogeneic hematopoietic cell transplantation (HCT) remains to be elucidated in the ruxolitinib era. We constructed a Markov model to simulate the 5-year clinical course of transplant candidates with PMF, and compared
-
Histamine dihydrochloride and low-dose interleukin-2 has antileukemic efficacy in NPM1-mutated and myelomonocytic/monocytic acute myeloid leukemia. Haematologica (IF 8.2) Pub Date : 2024-06-20 Malin S Nilsson, Michael Fiegl, Wolfgang Hiddemann, Wolfgang R Sperr, Fredrik B Thorén, Anna Martner, Kristoffer Hellstrand
Not available.
-
Clinical impact of clonal hematopoiesis in hematopoietic cell transplantation: a review, metaanalysis, and call to action. Haematologica (IF 8.2) Pub Date : 2024-06-20 Nancy Gillis, Amr Ebied, Zachary J Thompson, Joseph A Pidala
Hematopoietic cell transplantation (HCT) is the only potentially curative treatment option for many patients with hematologic malignancies. While HCT outcomes have improved drastically over the years, patients and clinicians continue to face numerous survivorship challenges, such as relapse, graft-versushost disease, and secondary malignancies. Recent literature suggests that clonal hematopoiesis (CH)
-
Anti-CD19 chimeric antigen receptor T-cell therapy has less efficacy in Richter transformation than in de novo large B-cell lymphoma and transformed low-grade B-cell lymphoma. Haematologica (IF 8.2) Pub Date : 2024-06-20 Ohad Benjamini, Shalev Fried, Roni Shouval, Jessica R Flynn, Ofrat Beyar-Katz, Lori A Leslie, Tsilla Zucherman, Ronit Yerushalmi, Noga Shem-Tov, Maria Lia Palomba, Ivetta Danylesko, Inbal Sdayoor, Hila Malka, Orit Itzhaki, Hyung Suh, Sean M Devlin, Ronit Marcus, Parastoo B Dahi, Elad Jacoby, Gunjan L Shah, Craig S Sauter, Andrew Ip, Miguel-Angel Perales, Arnon Nagler, Avichai Shimoni, Michael Scordo
The activity of anti-CD19 CAR T cell therapy in chronic lymphocytic leukemia (CLL) with Richter's transformation (RT) to aggressive large B cell lymphoma (LBCL) is largely unknown. In a multicenter retrospective study, we report the safety and efficacy of CAR T cell therapy in patients with RT (n=30) compared to patients with aggressive B cell lymphoma (n=283) and patients with transformed indolent
-
Brexucabtagene autoleucel in relapsed or refractory mantle cell lymphoma, intention-to-treat use in the DESCAR-T registry. Haematologica (IF 8.2) Pub Date : 2024-06-20 Charles Herbaux, Caroline Bret, Emmanuel Bachy, Pierre Bories, Roberta Di Blasi, Alexis Cuffel, Thomas Gastinne, Thierry Lamy, Mikael Roussel, Krimo Bouabdallah, David Beauvais, Guillaume Cartron, Jacques-Olivier Bay, Didier Blaise, Marie-Therese Rubio, Mohamad Mohty, Fabien Le Bras, Olivier Casasnovas, Julien Guy, Stephanie Guidez, Cristina Castilla Llorente, Olivier Hermine, Laurianne Drieu La Rochelle
Not available.
-
Event-free survival at 36 months is a suitable endpoint for diffuse large B-cell lymphoma patients treated with immunochemotherapy: real-world evidence from the North Japan Hematology Study Group. Haematologica (IF 8.2) Pub Date : 2024-06-13 Koh Izumiyama, Tasuku Inao, Hideki Goto, Shinpei Harada, Hajime Senjo, Keito Suto, Junichi Hashiguchi, Reiki Ogasawara, Tomoyuki Saga, Tetsuyuki Igarashi, Kentaro Wakasa, Ikumi Kasahara, Yukari Takeda, Keisuke Yamaguchi, Akio Shigematsu, Mutsumi Takahata, Katsuya Fujimoto, Yoshihito Haseyama, Takahiro Nagashima, Hajime Sakai, Yasutaka Kakinoki, Mitsutoshi Kurosawa, Isao Yokota, Takanori Teshima
Information regarding follow-up duration after treatment for newly diagnosed diffuse large B-cell lymphoma (DLBCL) is important. However, a clear endpoint has yet to be established. We totally enrolled 2182 patients newly diagnosed with DLBCL between 2008 and 2018. The median age of the patients was 71 years. All patients were treated with rituximab- and anthracycline-based chemotherapies. Each overall
-
Changes in sex-specific incidence of lymphoid neoplasms across the lifespan. Haematologica (IF 8.2) Pub Date : 2024-06-13 Bryan Valcarcel, Sara J Schonfeld, Sarah S Jackson, Graça M Dores, Martha S Linet, Lindsay M Morton
Not available.
-
Azacitidine as epigenetic priming for chemotherapy is safe and well-tolerated in infants with newly diagnosed KMT2A-rearranged acute lymphoblastic leukemia: Children's Oncology Group trial AALL15P1. Haematologica (IF 8.2) Pub Date : 2024-06-13 Erin M Guest, John A Kairalla, Meenakshi Devidas, Emily Hibbitts, Andrew J Carroll, Nyla A Heerema, Holly R Kubaney, Margaret A August, Sidharth Ramesh, Byunggil Yoo, Midhat S Farooqi, Melinda G Pauly, Daniel S Wechsler, Rodney R Miles, Joel M Reid, Cynthia D Kihei, Lia Gore, Elizabeth A Raetz, Stephen P Hunger, Mignon L Loh, Patrick A Brown
Infants less than 1 year old diagnosed with KMT2A-rearranged (KMT2A-r) acute lymphoblastic leukemia (ALL) are at high risk of remission failure, relapse, and death due to leukemia, despite intensive therapies. Infant KMT2A-r ALL blasts are characterized by DNA hypermethylation. Epigenetic priming with DNA methyltransferase inhibitors increases the cytotoxicity of chemotherapy in preclinical studies
-
An investigation of germline variants of HAVCR2 in subcutaneous panniculitis-like T-cell lymphoma and related lesions in a North American population. Haematologica (IF 8.2) Pub Date : 2024-06-13 Jinjun Cheng, Liqiang Xi, Yoon Jang, Jung Kim, Hao-Wei Wang, Stefania Pittaluga, Elaine S Jaffe, Mark Raffeld
Not available.
-
Epigenetic regulation of megakaryopoiesis and platelet formation. Haematologica (IF 8.2) Pub Date : 2024-06-13 Baichuan Xu, Xianpeng Ye, Zhaoyang Wen, Shilei Chen, Junping Wang
Platelets, produced by megakaryocytes, play unique roles in physiological processes, such as hemostasis, coagulation, and immune regulation, while also contributing to various clinical diseases. During megakaryocyte differentiation, the morphology and function of cells undergo significant changes due to the programmed expression of a series of genes. Epigenetic changes modify gene expression without
-
PD-1 blockade and allogeneic hematopoietic stem cell transplantation in Hodgkin lymphoma, a matter of time: a national study on behalf of the Société Francophone de Greffe de Moelle et de Thérapie Cellulaire. Haematologica (IF 8.2) Pub Date : 2024-06-13 Eleonore Kaphan, Francois Bettega, Nicolas Vallet, Nathalie Fegueux, Marie Robin, Ali Bazarbachi, Stephanie Nguyen, David Beauvais, Edouard Forcade, Maria Carolina Montes De Oca, Raynier Devillier, Patrice Chevallier, Michael Loschi, Anne Huynh, Jacques-Olivier Bay, Marie-Therese Rubio, Felipe Suarez, Sylvie Francois, Xavier Poire, Nathalie Contentin, Deborah Desmier, Amandine Charbonnier, Jerome Cornillon
Not available.
-
De-escalation of corticosteroids and clonal remission in UBA1 mutation-driven VEXAS syndrome with 5-azacytidine. Haematologica (IF 8.2) Pub Date : 2024-06-13 Roochi Trikha, Kar Lok Kong, James Galloway, Tanya N Basu, Lynn Quek, Jamie Wilson, Louise Gamble, Henna Wong, Steven Best, Austin Kulasekararaj
Not available.
-
Soluble SLAMF7 is generated by alternative splicing in multiple myeloma cells. Haematologica (IF 8.2) Pub Date : 2024-06-13 Jiro Kikuchi, Mitsuo Hori, Naoki Osada, Sae Matsuoka, Atsushi Suzuki, Satoshi Kakugawa, Hiroshi Yasui, Takeshi Harada, Hirofumi Tenshin, Masahiro Abe, Hideki Nakasone, Yusuke Furukawa
Not available.
-
IKZF1 gene deletions drive resistance to cytarabine in B-cell precursor acute lymphoblastic leukemia. Haematologica (IF 8.2) Pub Date : 2024-06-06 Britt M T Vervoort, Miriam Butler, Kari J T Grünewald, Dorette S van Ingen Schenau, Trisha M Tee, Luc Lucas, Alwin D R Huitema, Judith M Boer, Beat C Bornhauser, Jean-Pierre Bourquin, Peter M Hoogerbrugge, Vincent H J Van der Velden, Roland P Kuiper, Laurens T Van der Meer, Frank N Van Leeuwen
IKZF1-deletions occur in 10-15% of patients with B-cell precursor acute lymphoblastic leukemia (BCP-ALL) and predict a poor outcome. However, the impact of IKZF1-loss on sensitivity to drugs used in contemporary treatment protocols has remained underexplored. Here we show in experimental models and in patients that loss of IKZF1 promotes resistance to AraC, a key component of both upfront and relapsed
-
Reply to the Comment on Dexamethasone treatment for COVID-19 is related to increased mortality in hematologic malignancy patients: results from the EPICOVIDEHA Registry. Haematologica (IF 8.2) Pub Date : 2024-06-06 Tommaso Francesco Aiello, Carolina Garcia-Vidal
Not available.
-
Epstein-Barr Virus and immune status imprint the immunogenomics of non-Hodgkin lymphomas occurring in immune-suppressed environments. Haematologica (IF 8.2) Pub Date : 2024-06-06 Marine Baron, Karim Labreche, Marianne Veyri, Nathalie Désiré, Amira Bouzidi, Fatou Seck-Thiam, Frédéric Charlotte, Alice Rousseau, Véronique Morin, Cécilia Nakid-Cordero, Baptiste Abbar, Alberto Picca, Marie Le Cann, Noureddine Balegroune, Nicolas Gauthier, Ioannis Theodorou, Mehdi Touat, Véronique Morel, Franck Bielle, Assia Samri, Agusti Alentorn, Marc Sanson, Damien Roos-Weil, Corinne Haioun, Elsa
Non-Hodgkin lymphomas (NHL) commonly occur in immune-deficient (ID) patients, both HIV-infected and transplanted, and are often EBV-driven with cerebral localization, raising the question of tumor immunogenicity, a critical issue for treatment responses. We investigated the immunogenomics of 68 lymphoproliferative disorders from 51 ID (34 posttransplant, 17 HIV+) and 17 immunocompetent patients. Overall
-
Long-term efficacy and safety of tucidinostat in patients with relapsed or refractory peripheral T-cell lymphoma: final analysis of phase IIb results. Haematologica (IF 8.2) Pub Date : 2024-06-06 Shinya Rai, Won Seog Kim, Kiyoshi Ando, Ilseung Choi, Koji Izutsu, Norifumi Tsukamoto, Dai Maruyama, Kunihiro Tsukasaki, Junya Kuroda, Jun Ando, Michihiro Hidaka, Youngil Koh, Hisashi Kato, Toshiki Uchida, Deok Hwan Yang, Kenji Ishitsuka, Kenichi Ishizawa, Jin Seok Kim, Hong Ghi Lee, Hironobu Minami, Hyeon Seok Eom, Mitsutoshi Kurosawa, Jae Hoon Lee, Jong Seok Lee, Won Sik Lee, Hirokazu Nagai, Takero
Not available.
-
Ethnic diversity in presentation and outcome of Waldenström macroglobulinemia and IgM monoclonal gammopathy of clinical significance in the United Kingdom. Haematologica (IF 8.2) Pub Date : 2024-06-06 Jahanzaib Khwaja, Nicole Japzon, Maria Gabriel, Oliver Tomkins, Jindriska Lindsay, Charalampia Kyriakou, Ashutosh Wechalekar, Shirley D'Sa
Not available.
-
Superior outcomes and high-risk features with carfilzomib, lenalidomide, and dexamethasone combination therapy for patients with relapsed and refractory multiple myeloma: Results of the multicenter KMMWP2201 study. Haematologica (IF 8.2) Pub Date : 2024-06-06 Ji Hyun Lee, Jimin Choi, Chang-Ki Min, Sung-Soo Park, Jae-Cheol Jo, Yoo Jin Lee, Jin Seok Kim, Hyeon-Seok Eom, Jongheon Jung, Joon Ho Moon, Hee Jeong Cho, Myung-Won Lee, Sung-Soo Yoon, Ja Min Byun, Jae Hoon Lee, Je-Jung Lee, Sung-Hoon Jung, Ho-Jin Shin, Do Young Kim, Jun Ho Yi, Seung-Shin Lee, Young Rok Do, Dok Hyun Yoon, Hyungwoo Cho, Won Sik Lee, Ho Sup Lee, Jieun Uhm, Hyo Jung Kim, Hee Ryeong Jang
Carfilzomib, lenalidomide, and dexamethasone (KRd) combination therapy improves the survival of patients with relapsed and/or refractory multiple myeloma (RRMM). Nonetheless, evidence on the use of KRd in Asian populations remains scarce. Accordingly, this study aimed at investigating this regimen's efficacy in a large group of patients. This retrospective study included patients with RRMM who were
-
Impact of genetic alterations on central nervous system progression of primary vitreoretinal lymphoma. Haematologica (IF 8.2) Pub Date : 2024-06-06 Kota Yoshifuji, Daichi Sadato, Takashi Toya, Yotaro Motomura, Chizuko Hirama, Hiroshi Takase, Kouhei Yamamoto, Yuka Harada, Takehiko Mori, Toshikage Nagao
Primary vitreoretinal lymphoma (PVRL) is a rare malignant lymphoma subtype with an unfavorable prognosis due to frequent central nervous system (CNS) progression. Thus, identifying factors associated with CNS progression is essential for improving the prognosis of PVRL patients. Accordingly, we conducted a comprehensive genetic analysis using archived vitreous humor samples of 36 PVRL patients diagnosed